Since the stabilization of GLP-1 through DPP4 inhibitors resulted in increased bioavailability of and sensitivity to insulin [126], and since DPP4 inhibitors have a positive effect on hypercholesterolemia, which also interferes with arteriogenesis [127], DPP4 inhibitors might not only restore arteriogenesis in type 2 DM patients, but even enhance it due to the local increase of SDF-1 levels. Here, DPP4 is linked to Hypercholesterolemia.